OpportunityAnalyzer: Vasculitis – Opportunity Analysis and Forecast to 2024
All the vital news, analysis, and commentary curated by our industry experts.
Vasculitis is a family of rare autoimmune diseases, causing inflammation of the blood vessels, arteries, veins or capillaries. The different forms of vasculitis are classified by the size and location of the affected blood vessels . This report specifically covers large vessel vasculitis (LLV), Kawasaki disease (KD), antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), and Behçet's disease (BD). In 2014, there were 137,603 and 82,501 diagnosed prevalent and incident cases in the 7MM (US, France, Germany, Spain, Italy, UK, and Japan), respectively. Untreated, the organs and tissues affected by the damaged blood vessels do not get enough blood, which can lead to organ or tissue damage, or even death. J&J's Remicade was the first biologic in the vasculitis market, approved for BD in Japan in 2007. Other biologics approved for vasculitis include AbbVie's Humira for BD in Japan and Biogen/Roche's Rituxan for GPA/MPA in the 7MM. Several unmet needs still remain such as the development of drugs with improved safety and efficacy for use in both the induction and maintenance treatment settings . GlobalData expects the launch of six drugs during the 2014 to 2024 forecast period along with increased diagnosed patient numbers will drive the vasculitis market.
Overview of vasculitis, including etiology, pathophysiology, and country-specific diagnosis and treatment recommendations.
Annualized vasculitis market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
Key topics covered include strategic competitor assessment, market characterization, unmet needs, and implications for the vasculitis market.
Pipeline analysis: comprehensive data split across different phases and emerging trends, specifically BMS’s Orencia, GSK’s Benlysta and Nucala, Genentech/Roche’s Actemra, Celgene’s Otezla, J&J’s Remicade, and biosimilars (such as Celltrion/Hospira/Alvogen’s Inflectra/Remsima).
Analysis of the current and future market competition in the global vasculitis market. Insightful review of the key industry and governmental drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
How large an impact will biosimilars have on the vasculitis market? What do vasculitis specialists and key opinion leaders across the 7MM think about the evolving treatment landscape?
What opportunities remain in the market for new product entrants?
With six drug launches, five of which are biologics, which products are forecast to generate the highest sales over 2014-2024? How are product launches expected to affect the sales of induction and maintenance therapies?
According to KOLs, what are the most important unmet needs in vasculitis? Will these needs be addressed by pipeline agents? What needs will remain by the end of the forecast period in 2024?
What industry developments are likely to affect sales of the top-selling vasculitis drugs in the markets researched? Which is the largest growth market globally?
Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Types of Vasculitis
3.2 Etiology and Pathophysiology
3.2.1 Large Vessel Vasculitis
3.2.2 Kawasaki Disease
3.2.3 ANCA-Associated Small Vessel Vasculitis
3.2.4 Behҫet’s Disease
3.4 Disease Management
3.4.1 Classification Criteria
3.4.2 Disease Management Guidelines
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global Trends
4.4 Forecast Methodology
4.4.1 Sources Used
4.4.2 Sources Not Used
4.4.3 Forecast Assumptions and Methods
4.5 Epidemiological Forecast for Vasculitis, 2014–2024
4.5.1 Diagnosed Incident Cases of AAV
4.5.2 Diagnosed Prevalent Cases of AAV
4.5.3 Age-Standardized Incidence of AAV
4.5.4 Diagnosed Incident Cases of LVV – TA and GCA
4.5.5 Diagnosed Prevalent Cases of TA
4.5.6 Age-Standardized Incidence of LVV
4.5.7 Diagnosed Incident Cases of BD
4.5.8 Diagnosed Prevalent Cases of BD
4.5.9 Age-Standardized Incidence of BD
4.5.10 Diagnosed Incident Cases of KD
4.6.1 Epidemiological Forecast Insight
4.6.2 Limitations of the Analysis
4.6.3 Strengths of the Analysis
5 Current Treatment Options
5.2 Product Profiles
5.2.1 Rituxan (Rituximab)
5.2.2 Humira (Adalimumab)
5.2.3 Remicade (Infliximab)
5.2.4 Mycophenolate Mofetil
5.2.9 Intravenous Immunoglobulin
6 Unmet Needs Assessment and Opportunity Analysis
6.2 Improved Drug Efficacy and Safety in the Induction Therapy Setting
6.2.1 Unmet Need
6.2.2 Gap Analysis
6.3 Improved Drug Efficacy and Safety in the Maintenance Therapy Setting
6.3.1 Unmet Need
6.3.2 Gap Analysis
6.4 Biomarkers to Predict Responsiveness to Therapy
6.4.1 Unmet Need
6.4.2 Gap Analysis
6.5 Biomarkers to Predict Disease Relapse
6.5.1 Unmet Need
6.5.2 Gap Analysis
6.6 Early and Non-invasive Diagnosis of Vasculitis
6.6.1 Unmet Need
6.6.2 Gap Analysis
6.7 Adjunctive Therapy for the Treatment of KD
6.7.1 Unmet Need
6.7.2 Gap Analysis
7 R&D Strategies
7.2 Expansion for Key Autoimmune Drugs
7.3 Shift Towards Vasculitis as a Primary Indication
7.4 Clinical Trial Design
7.4.1 Current Clinical Trial Design
7.4.2 Challenges in Vasculitis Clinical Trial Design
8 Pipeline Assessment
8.2 Promising Drugs in Clinical Development
8.2.1 Orencia (Abatacept)
8.2.2 Benlysta (Belimumab)
8.2.3 Actemra (Tocilizumab)
8.2.4 Otezla (Apremilast)
8.2.5 Nucala (Mepolizumab)
8.3 Additional Drugs in Development for Vasculitis
9 Pipeline Valuation Analysis
9.1 Clinical Benchmark of Key Pipeline Drugs
9.2 Commercial Benchmark of Key Pipeline Drugs
9.3 Competitive Assessment
9.4 Top Line Ten Year Forecast
10.4 Forecasting Methodology
10.4.1 Percent Drug-treated Patients
10.4.2 Drugs Included in Each Therapeutic Class
10.4.3 Launch and Patent Expiry Dates
10.4.4 General Pricing Assumptions
10.4.5 Individual Drug Assumptions
10.4.6 Generic Erosion
10.4.7 Pricing of Pipeline Agents
10.5 Primary Research
10.5.1 Physicians and Specialists Included in this Study
10.5.2 Online Survey of High Prescribing Physicians
10.6 About the Authors
10.6.4 Global Director of Therapy Analysis and Epidemiology
10.6.5 Global Head of Healthcare
10.7 About GlobalData
Frequently asked questions
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Business Intelligence & Marketing Manager, SAL Heavy Lift
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
Market Analyst & Management, Liebherr-Werk
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Head of Key Accounts, Saab AB
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Marketing Intelligence Manager, Portugal Foods
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Head of Customer Insight and Research, Standard Chartered
Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.
I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.
I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.
Head of Consumer Sensory Insights, Givaudan
“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.
Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”
Senior Account Manager, TSYS
GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.
I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.
One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.